Clinical Trial

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This pilot study is configured as a non-inferiority comparison of Performance Status 2 patients with Performance Status 0-1 patients, with the goal of demonstrating non-inferiority in terms of efficacy (progression-free survival, overall survival) and safety (rates of adverse events, quality of life) when treating Performance Status 2 patients with the same first-line immunotherapy-based regimen as Performance Status 0-1 patients.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-09 -> 2027-09-01 2026-08-11
minor Completion pushed: 2026-09 -> 2027-09-01 2026-08-11
Trial Details
NCT Number NCT04253964
Lead Sponsor Wake Forest University Health Sciences
Collaborators: National Cancer Institute (NCI)
Conditions Nonsmall Cell Lung Cancer, Performance Status
Enrollment 105 participants
Start Date 2020-07-01
Primary Completion 2027-09-01 (estimated)
Study Completion 2027-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-10